ISSN: 1300-7777 E-ISSN: 1308-5263
Imatinib mesylate and the management of chronic myeloid leukemia (CML) [Turk J Hematol]
Turk J Hematol. 2005; 22(4): 161-172

Imatinib mesylate and the management of chronic myeloid leukemia (CML)

Ebru Koca, İbrahim C. Haznedaroğlu
Department Of Internal Medicine, Hematology Unit, Hacettepe University School Of Medicine, Ankara, Turkey

Keywords: Chronic myeloid leukemia (CML), Imatinib mesylate, BCR-ABL, Signal transduction inhibitor.


Ebru Koca, İbrahim C. Haznedaroğlu. Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turk J Hematol. 2005; 22(4): 161-172

Corresponding Author: İbrahim C. Haznedaroğlu, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2017) = 0.650